Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

5-hydroxymethylcytosine loss is associated with poor prognosis for patients with WHO grade II diffuse astrocytomas.

Scientific reports - 11 Feb 2016

Zhang Feng, Liu Yifan, Zhang Zhiwen, Li Jie, Wan Yi, Zhang Liying, Wang Yangmei, Li Xia, Xu Yuqiao, Fu Xin, Zhang Xiumin, Zhang Ming, Zhang Zhekai, Zhang Jing, Yan Qingguo, Ye Jing, Wang Zhe, Chen Charlie Degui, Lin Wei, Li Qing

Abstract excerpt

Currently, the reliable prognostic biomarkers for WHO grade II diffuse astrocytomas (DA) are still limited. We investigated the relations between the level of 5-Hydroxymethylcytosine (5hmC), an oxidated production of 5-methylcytosine (5mC) by the ten eleven translocated (TET) enzymes, and clinicopathological features of glioma patients. With an identified anti-5hmC antibody, we performed immunohistochemistry in...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to 5-Methylcytosine
Share to Antibodies

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Astrocytoma

Share to Central Nervous System Neoplasms

Share to Cytosine

Share to Ki-67 Antigen

Share to Neoplasm Grading

Share to Spinal Cord

Source

Open in PubMed Open full text

Identifiers

PMID: 26864347
DOI: 10.1038/srep20882
PMCID: PMC4749994

Genes

IDH1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

5-hydroxymethylcytosine loss is associated with poor prognosis for patients with WHO grade II diffuse astrocytomas.PMID 26864347Read ↗

Genetic Characterization of Ten-Eleven-Translocation Methylcytosine Dioxygenase Alterations in Human GliomaSemantic proximity Read ↗

Nuclear exclusion of TET1 is associated with loss of 5-hydroxymethylcytosine in IDH1 wild-type gliomas.Semantic proximity Read ↗

Low values of 5-hydroxymethylcytosine (5hmC), the "sixth base," are associated with anaplasia in human brain tumors.Semantic proximity Read ↗

IDH mutation, 1p19q codeletion and ATRX loss in WHO grade II gliomas.Semantic proximity Read ↗

Loss of 5-Hydroxymethylcytosine as an Epigenetic Signature that Correlates with Poor Outcomes in Patients with MedulloblastomaSemantic proximity Read ↗

Region-specific DNA hydroxymethylation along the malignant progression of IDH-mutant gliomas.Semantic proximity Read ↗

TET CpG sequence-context-specific DNA demethylation shapes progression of IDH-mutant gliomas.Semantic proximity Read ↗

Loss of 5-hydroxymethylcytosine and intratumoral heterogeneity as an epigenomic hallmark of glioblastoma.Semantic proximity Read ↗

5-Hydroxymethylcytosine: a key epigenetic mark in cancer and chemotherapy responseSemantic proximity Read ↗

High-throughput sequencing offers new insights into 5-hydroxymethylcytosine.Semantic proximity Read ↗

Molecular signature of SETD2 and m6A modifiers in the pathogenesis of different grades of adult-type diffuse gliomas.Semantic proximity Read ↗

Immunohistochemical profiles of I DH 1, MGMT and P 53: Practical significance for prognostication of patients with diffuse gliomasSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.